Peer Review History
Original SubmissionApril 28, 2020 |
---|
PONE-D-20-12369 Full-title: Antibody Response to Malaria Merozoite Antigens in Asymptomatic Children Co-infected with Malaria and Intestinal Parasites PLOS ONE Dear Dr. Ndiabamoh, Thank you for submitting your manuscript to PLoS ONE. After careful consideration, we felt that your manuscript requires substantial revision, following which it can possibly be reconsidered, thus governing the decision of a “major revision”. As requested by the reviewers, the authors need to address several concerns, particularly related to the study design, methods and results. A major concern raised by the Reviewers was because parasite detection was not followed by sensitive diagnostic techniques such as PCR-based assays, and submicroscopic infections may have been missed. Finally, the authors should follow the policy of Plos One to share the raw data underlying their results. Such policies help increase the reproducibility of the published literature, as well as make a larger body of data available for reuse and re-analysis. For your guidance, a copy of the reviewers' comments was included below. Please submit your revised manuscript by July 10. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Luzia Helena Carvalho, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following in the Acknowledgments Section of your manuscript: "Funding Statement: The beats used for the experiments were a gift from A. Babakhanyan (University of Hawaii) and coupled by ELG. The MAGPIX used for the data analysis was MAGPX I3038703, Luminex corporation 12212 technology Blvd Austin. Texas 78727. GFLR provided the funds for the field work and analysis" We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. * Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "The author(s) received no specific funding for this work. Funding used in for this research was mentors (Prof Leke Rose) and a Gift of the magnetic beats from Dr Anna Babakhanyan. No other specific funding were received. " Additionally, because some of your funding information pertains to [commercial funding//patents], we ask you to provide an updated Competing Interests statement, declaring all sources of commercial funding. In your Competing Interests statement, please confirm that your commercial funding does not alter your adherence to PLOS ONE Editorial policies and criteria by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests. If this statement is not true and your adherence to PLOS policies on sharing data and materials is altered, please explain how. * Please include the updated Competing Interests Statement and Funding Statement in your cover letter. We will change the online submission form on your behalf. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Dr. Mbe-cho and colleagues sought to determine the prevalence of co-infection of malaria and intestinal parasites and its association with antibody levels to malaria merozoite antigens. The authors report that there was no difference in antibody prevalence or levels in malaria-infected and co-infected children, except antibody levels to EBA-175 were significantly higher in children co-infected with malaria and E. histolytica. Overall, the study is well-designed but these results do not significantly alter or impact our understanding of the association of malaria and helminths on antibody to malaria merozoite antigens. 1. The limitation of the study is that the parasite testing in children was not followed by sensitive diagnostic techniques like PCR, and light infections may have been missed which may have resulted in misclassification of the groups. Light infections may boost the antibody responses while children remain asymptomatic. 2. In this study, only 3.4% children were infected with helminths alone to get any meaningful data for antibody response to malaria in this group. 3. Very few children are positive for E. histolytica. 4. The data on the children's anthropomorphic measurements are not mentioned. Thus, there is not much point describing how they were collected. 5. There is no data on hookworm infection in the results. 6. The number of eggs per gram of stool were estimated for the parasites listed. Did the authors look at the responses in children with high or low intensity of the parasites? 7. Table 2 is not necessary, it can be written as text. 8. Page 21, reference # 54, year of publication is missing. Please check spelling and typographical errors scattered through the manuscript (page and lines are given from word document): 1. Page 2, line 3, change led to lead in the sentence. 2. Page 2, line 14, correct the spelling of Rietchi concentration method 3. Page 6, line 21: The bracket has to be closed here: (AB Leo Diagnostics, Helsingborg, Sweden. 4. Page 7, line 17 and 18: Correct 50ul to 50µl 5. Page 9 and 10: In the text, the p value for anemia (MAL+,IP-) is p=0.034; p value for the same in Table 1 is p=0.032; it needs to be corrected. 6. Page 10: In Table 1, % sign is missing in column 5 for children with Hb. 7. Page 10, line 3: In the sentence, change major to majority. 8. Page 14, line 27: In the sentence, MSL- should be MAL- 9. Page 17, line 15: change beats to beads Re-write the following sentences, they are not very clear: Page 4, line 8: However, with most children getting infected with several episodes of infections in a short period, this renders them more prone to having clinical symptoms since the immune systems doesn’t fully recover. Page 4, line 20: Concomitant infections in humans have suggested that Ascaris lumbricoides infection may protect against cerebral malaria (11,12), while other studies, children infected by S. mansoni were more susceptible to P. falciparum infection and develop acute malaria episodes. Page 15, line 3: In essence, the immune response in individuals who are repeatedly infection would be similar to that produce during chronic infections. Reviewer #2: The answer to the questions is divided into Major comments, Minor comments. Additionally, I wrote minor observations that, I hope, will help this manuscript to improve readability and consistency. 1. Is the manuscript technically sound, and do the data support the conclusions? 2. Has the statistical analysis been performed appropriately and rigorously? 3. Have the authors made all data underlying the findings in their manuscript fully available? 4. Is the manuscript presented in an intelligible fashion and written in standard English? Major comments: • Given that there were no differences in the IgG response between age groups, it would be interesting to join these data, evaluate all the coinfected individuals, and then split the data into Giardia, E. hystolitica. • I strongly suggest dividing the age of individuals in 0-5, 5-10, 10-15 years-old to partially solve the "N" problem of the groups. • Because of the absence of molecular Diagnosis and considering that the authors mention the possibility of oh having low parasitemia infections in the MAL- group. It is important to include MAL- individuals in Figure 1. • It is necessary to compare parasite data with similar regions in Cameroon. Please compare and cite: • (Malaria and Helminth Co-Infection in Children Living in a Malaria Endemic Setting of Mount Cameroon and Predictors of Anemia from Theresa K Nkuo-Akenji et al. 2006) • Malaria, Helminths, Coinfection and Anaemia in a Cohort of Children From Mutengene, South Western Cameroon from Clarisse Njua-Yafi et al. 2016. • Do the authors have information about malaria and intestinal parasites last treatments? On page 17, it was commented that Albendazole treatment was frequent in these children. Deworming information will help the readers to understand why the prevalence of intestinal parasites was low compared with other studies in Cameroon. Additionally, reinforce in the discussion section that collecting/reporting that information is valuable for coinfection studies. • (Figure 1 B, C, D, E) use the same scale limits for all plots. This is also useful to understand differences in levels of antigenicity between proteins. • (table 3) How could the authors explain increased eosinophilia with low levels of helminth infection? This mainly applies to the age group > 9 years-old. • (Page 17) The authors argue, "First, children living in moist or wet environments where mosquitoes breed and E. histolytica are more abundant would have a high risk of acquiring both infections, that would result in frequent boosting of the Ab response." This explanation for intestinal parasite influence on antibody production alteration is not viable since Giardia's frequency is higher than E. hystolitica in the studied population. • (Page 17) The affirmation "Secondly, since malaria and E. histolytica are both amoebae, they might share common antigens, for example, EBA-175 could share homology with an E. histolytica antigen." is false. Plasmodium falciparum is not an is a protozoan. This group belongs to Apicomplexa organisms. For that reason, the hypothesis about correlating Plasmodium and E. hystolitica is wrong. • How different are the two Villages Ngali II and Mfou in the central region of Cameroon? Does it exist a difference in humidity and soil moist, once the authors claimed that this variable could explain differences of Entamoeba histolytica? Minor comments: • What criteria were used to divide the population into seven groups according to age? • Please specify how anthropometric parameters were used in the study, once they were described but not used in the study. If this information was not used, please remove these sentences. • Has the studied region presence of Schistosoma haematobium? If the authors have register if this parasite in the area, Did they examined urine samples to discard infections with this parasite? • Were the individuals asymptomatic to intestinal parasites infection too? No diarrhea, abdominal pain, etc.? Please clarify. • (Page 6) It was mentioned that Plasmodium parasitemia was quantified. Did the authors observe any correlation between the Plasmodium parasite burden and the levels of IgG responses to the antigens? • (End of Page 7) Please specify: If the cut-off is MFI+3*SD, how the standard deviation was calculated if the negative controls were pooled? Was this experiment repeated or used replicates? Traditionally, the negative controls are tested simultaneously in different wells of the plate, and the cut-off is calculated from those values. • Did the authors analyze the effect of helminth parasite burden (number of eggs/gram of stool) in those individuals with helminths? This valuable information was commented on but never included in the analysis. If not used,e I do not see the necessity of describing in the methods section • For data analysis: • Before using ANOVA, did the authors checked for the normality of the variables? If yes, please specify, if not, calculate the normality of the variables and the other ANOVA assumptions. • If the authors have not-normal variables, they should use the Kruskal-Wallis non-parametric, and Dunn posthoc tests to verify differences between groups. • Please check frequencies described in table 1 (MAL+IP- 58.8%) vs. the values reported in the second line page 9. (59.4%). • Sum of 58.8%+16.9% = 75.7% not 75.6%. • In table 1, please add a column with P-values to facilitate the interpretation of the differences between groups. Please report statistics of multiple comparisons between groups too. • What is the potential hypothesis to explain the increased values of parasitemia in the coinfected group? • Please comment in the text the presence of multiparasitism in the studied individuals. • (Page 11 table 3). Please include values of anemia and eosinophilia in individuals coinfected. In the current configuration is constructed is hard to determine the coinfection impact in anemia and eosinophilia values. • (Page 11). In the sentence, "Thus, as children living in these villages increased with age, they developed partial immunity to malaria and anemia declined; whereas, the prevalence of IP and eosinophilia increased." In this sentence, it is necessary to specify that "protection" is protection against malaria symptoms. The table clearly shows that the frequency of malaria does not decrease with age, only the anemia. • Please plot Age vs. Antibody levels for each protein to verify the correlation for each protein studied. • As an exploratory analysis, I suggest joining all data and make a boxplot comparing MFI between MAl-PI-, MAL-PI+, MAL+PI-, and MAL+PI+. Mainly for MSP1, MPS2, and MSP3 group age 3-10 and 11-15 to check. • The sentence "E. histolytica is a gut amoeba that causes both intestinal and extraintestinal infections such as amebic colitis (dysentery) and liver or brain abscess. The protozoa cause a marked down-regulation of macrophage functions rendering the cells incapable of antigen presentation and unresponsive to cytokine stimulation (57)" does not explain the increase of antibody production in E. histolytica infected group. Why could a diminishing antigen presentation generate higher levels of anti-Plasmodium antigens? Other observations/questions: • In the title, add "IgG" to Antibody response. • Check all scientific names of parasite species for correct formatting in italics. (Example Entamoeba histolytica in the Results section in the abstract) • Please, mention in the background the region where the study was performed. • It is necessary to describe and discuss the role of MSP1, MPS2, MSP3, and EBA-175 as markers in serological studies. • Considering that coinfection prevalence is relatively low, I consider that it is important to discriminate with colors or point shapes the individuals MAL-IP-, MAL+IP-, MAL-IP+, MAL+IP+ in Figure 1 B-C-D-E • In page 6 subtitle "Laboratory detection, quantification and speciation of malaria parasites.", I will not use speciation here. I suggest "Diagnosis and quantification of Plasmodium sp. parasites. • (Page 14-15) What type of parasite is "Amoeba"? What is the difference between "Amoeba" and E. hystolitica? Traditionally, E. hystolitica is considered an amoeba too. • In table 1, to facilitate reading, please remove symbols % and /ul located in cells with data and add to the columns describing the variables. • For consistency, unify parasitemia vs. parasitaemia, anemia vs. anaemia in the text and plots. • (Page 10) change "The major of helminth parasites" to "The most frequent helminth species detected." • (table 2) Check all the total numbers for the "Total IP+" column. For example, for protozoans, the sum is 29+19+4 = 48, and it was reported 47 • (Page 13) In plot titles Change Ab (Antibody) to IgG • (Figure 1E) Add, Change from EBA to EBA-175. • Please verify all references formatting (For example, reference 42 is all in capital letters) Reviewer #3: Review Comments to the Author Please find attached the manuscript with my comments for the manuscript 'Full-title: Antibody Response to Malaria Merozoite Antigens in Asymptomatic Children Co-infected with Malaria and Intestinal Parasites' ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
Revision 1 |
PONE-D-20-12369R1 Full-title: The immunoglobulin G antibody response to malaria merozoite antigens in asymptomatic children co-infected with malaria and intestinal parasites PLOS ONE Dear Dr. Ndiabamoh Thank you for submitting your manuscript to PLoS ONE. After careful consideration, we felt that your study has the potential to be published if it is revised to address specific topics raised by the reviewers. A major concern was because the authors revised the MS just by deleting part of the text, without rewriting or providing additional analysis as requested. Also, it is essential to clarify in the abstract that population received mass drug administration, which may explain the lower prevalence of helminths/ protozoans. For your guidance, a copy of the reviewers' comments was included below. Please submit your revised manuscript by September 10. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Luzia Helena Carvalho, Ph.D. Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: (No Response) Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have addressed all the comments. There are some minor corrections: Line 36: Please correct the number of children, 244/230 to 244/320 Line 61: Please correct the species, Trichuria trichuria, to Trichuris trichiura Please use the reference style outlined by the International Committee of Medical Journal Editors (ICMJE) Reviewer #2: Comments: 1. Check carefully all the italics for species names 2. Is it necessary the sentence in the line 342 in italics? 3. As I previously commented, the discussion about MSP1, MSP2, and MPS3 role as maskers is absent. Please discuss and compare findings with other studies using the same proteins. 4. Please mention in results that hookworms were not detected in the study 5. Please mention in results that no significant difference was observed between the malaria antibodies levels and parasites eggs counts. 6. Although the authors specify two references describing the bead assay, I still believe it is important to report each antigen's concentration in the bead assay. Once the authors explained that these concentrations are not comparable. Additionally, in the references given (old 23 and 24), there is no information about how EBA175 was produced. 7. Please add references showing that eosinophilia is maintained in individuals that had intestinal infections during a longer time even after MDA. 8. The author explains that "The fact that Intestinal parasite (IP) infections was only observed in children >2 years, helped guide separation of the children into seven groups." But that is not e real explanation; please explain what the rationale for that separation is? Why not use 3-4-5-6 groups? 9. Please comment in the abstract that the population received mass drug administration. I consider that that is a crucial point of the investigation and explains the lower prevalence of helminths and protozoans. 10. I think it would be necessary for the manuscript to verify the existence of other articles reporting intestinal parasites in populations under MDA treatment and add that to the discussion. � Reviewer #3: Please see comments in the attached file ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
Revision 2 |
PONE-D-20-12369R2 Full-title: The immunoglobulin G antibody response to malaria merozoite antigens in asymptomatic children co-infected with malaria and intestinal parasites PLOS ONE Dear Dr. Ndiabamoh, After careful consideration, we have concluded that your manuscript has the potential to be published although some aspects of the manuscript will need to be changed prior to formal acceptance. More specifically, the authors should discuss in much more details the MSP-1/2/3 results comparing with other studies from the same/different areas/individuals. These comments would enrich the manuscript, even considering that the authors could not test the original coinfection effect hypothesis due to the lack of sample size. Please submit your revised manuscript by October 30. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Luzia Helena Carvalho, Ph.D. Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have addressed all the comments. There are some minor corrections: hook worm should be hookworm. Page 19 line 397; ref 59 has been written three times. Reviewer #2: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
Revision 3 |
Full-title: The immunoglobulin G antibody response to malaria merozoite antigens in asymptomatic children co-infected with malaria and intestinal parasites PONE-D-20-12369R3 Dear Dr. crespo'o mbe-cho ndiabamoh, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Luzia Helena Carvalho, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
Formally Accepted |
PONE-D-20-12369R3 The immunoglobulin G antibody response to malaria merozoite antigens in asymptomatic children co-infected with malaria and intestinal parasites Dear Dr. Ndiabamoh: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Luzia Helena Carvalho Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .